Therapy of Prostate Cancer Using a Human Antibody Targeting the Type 1 Insulin-Like Growth Factor Receptor (IGF-IR)

摘要

During this funding period we have shown that inhibition of the type 1 IGF receptor with a fully human monoclonal antibody can delay prostate cancer growth in intact and castrate human xenograft mouse models. Further IGF-IR inhibition of IGF-IR greatly enhanced the effects of castration and docetaxel on prostate cancer. There was a significant effect on prostate cancer when growing in bone, especially in combination with Docetaxel. There was no evidence of significant treatment toxicity. The results of these preclinical studies have led to phase 1 and 2 clinical trials in each instance.